Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis | Zendy

Davina J. Tai | Zendy; Thomas W. Lim | Zendy; Matthew T. James | Zendy; Braden Manns | Zendy; Marcello Tonelli | Zendy; Brenda R. Hemmelgarn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis

Author(s) -

Davina J. Tai,

Thomas W. Lim,

Matthew T. James,

Braden Manns,

Marcello Tonelli,

Brenda R. Hemmelgarn

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.07831109

Subject(s) - medicine , confidence interval , hemodialysis , population , relative risk , meta analysis , angiotensin converting enzyme , randomized controlled trial , cardiology , blood pressure , environmental health

Cardiovascular (CV) disease causes significant morbidity and mortality among the hemodialysis (HD) population. This meta-analysis was performed to determine whether angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) reduce fatal and nonfatal CV events and left ventricular (LV) mass in patients receiving HD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research